Globus Medical (GMED)
Market Price (4/11/2026): $90.41 | Market Cap: $12.2 BilSector: Health Care | Industry: Health Care Equipment
Globus Medical (GMED)
Market Price (4/11/2026): $90.41Market Cap: $12.2 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20% Megatrend and thematic driversMegatrends include Precision Medicine, and Automation & Robotics. Themes include Targeted Therapies, Personalized Diagnostics, Show more. | Weak multi-year price returns3Y Excs Rtn is -9.2% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 23x Key risksGMED key risks include [1] regulatory fallout from an FDA warning letter regarding its Excelsius GPS spine robot and [2] operational and supply chain disruptions stemming from the large-scale integration of its NuVasive acquisition. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 26%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 20% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Automation & Robotics. Themes include Targeted Therapies, Personalized Diagnostics, Show more. |
| Weak multi-year price returns3Y Excs Rtn is -9.2% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 23x |
| Key risksGMED key risks include [1] regulatory fallout from an FDA warning letter regarding its Excelsius GPS spine robot and [2] operational and supply chain disruptions stemming from the large-scale integration of its NuVasive acquisition. |
Qualitative Assessment
AI Analysis | Feedback
1. Strong Q4 2025 Earnings Performance and Positive 2026 Outlook Largely Priced In: Globus Medical reported robust fourth-quarter 2025 results on February 24, 2026, with an EPS of $1.28, significantly exceeding the consensus estimate of $1.06, and quarterly revenue increasing by 25.7% year-over-year to $826.42 million, surpassing analysts' expectations of $803.29 million. Additionally, the company reaffirmed its 2026 revenue guidance in the range of $3.18 billion to $3.22 billion and updated its non-GAAP fully diluted EPS guidance to between $4.40 and $4.50, up from a previous range of $4.30 to $4.40. While these figures indicate strong operational performance and a positive outlook, the market may have already factored in much of this anticipated growth, limiting significant upward movement beyond initial reactions.
2. Broader MedTech Industry Transition and Adaptation Challenges: The medical technology (MedTech) sector is currently navigating a pivotal phase in 2026, shifting focus from initial regulatory approvals to the more complex challenge of industrializing adoption and integrating new technologies into clinical workflows. This includes adapting to evolving FDA oversight and resource constraints, which can lead to delays for innovators, and retooling commercial and product-delivery models to align with the expansion of procedures, including spine cases, to Ambulatory Surgery Centers (ASCs) following new CMS rules. While these trends present growth opportunities for companies like Globus Medical, they also introduce operational complexities and necessitate strategic investments, potentially contributing to a more stabilized stock movement as the market assesses long-term adaptation capabilities.
Show more
Stock Movement Drivers
Fundamental Drivers
The 3.6% change in GMED stock from 12/31/2025 to 4/10/2026 was primarily driven by a 19.6% change in the company's Net Income Margin (%).| (LTM values as of) | 12312025 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 87.31 | 90.42 | 3.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,770 | 2,939 | 6.1% |
| Net Income Margin (%) | 15.3% | 18.3% | 19.6% |
| P/E Multiple | 27.7 | 22.6 | -18.5% |
| Shares Outstanding (Mil) | 135 | 134 | 0.1% |
| Cumulative Contribution | 3.6% |
Market Drivers
12/31/2025 to 4/10/2026| Return | Correlation | |
|---|---|---|
| GMED | 3.6% | |
| Market (SPY) | -5.4% | 35.1% |
| Sector (XLV) | -4.8% | 39.7% |
Fundamental Drivers
The 57.9% change in GMED stock from 9/30/2025 to 4/10/2026 was primarily driven by a 34.8% change in the company's Net Income Margin (%).| (LTM values as of) | 9302025 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 57.27 | 90.42 | 57.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,626 | 2,939 | 11.9% |
| Net Income Margin (%) | 13.6% | 18.3% | 34.8% |
| P/E Multiple | 21.7 | 22.6 | 4.1% |
| Shares Outstanding (Mil) | 135 | 134 | 0.6% |
| Cumulative Contribution | 57.9% |
Market Drivers
9/30/2025 to 4/10/2026| Return | Correlation | |
|---|---|---|
| GMED | 57.9% | |
| Market (SPY) | -2.9% | 24.6% |
| Sector (XLV) | 6.3% | 23.1% |
Fundamental Drivers
The 23.5% change in GMED stock from 3/31/2025 to 4/10/2026 was primarily driven by a 347.7% change in the company's Net Income Margin (%).| (LTM values as of) | 3312025 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 73.20 | 90.42 | 23.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,519 | 2,939 | 16.7% |
| Net Income Margin (%) | 4.1% | 18.3% | 347.7% |
| P/E Multiple | 97.2 | 22.6 | -76.8% |
| Shares Outstanding (Mil) | 137 | 134 | 1.7% |
| Cumulative Contribution | 23.5% |
Market Drivers
3/31/2025 to 4/10/2026| Return | Correlation | |
|---|---|---|
| GMED | 23.5% | |
| Market (SPY) | 16.3% | 35.0% |
| Sector (XLV) | 2.3% | 36.2% |
Fundamental Drivers
The 59.6% change in GMED stock from 3/31/2023 to 4/10/2026 was primarily driven by a 187.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312023 | 4102026 | Change |
|---|---|---|---|
| Stock Price ($) | 56.64 | 90.42 | 59.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,023 | 2,939 | 187.3% |
| Net Income Margin (%) | 18.6% | 18.3% | -1.6% |
| P/E Multiple | 29.8 | 22.6 | -24.1% |
| Shares Outstanding (Mil) | 100 | 134 | -25.6% |
| Cumulative Contribution | 59.6% |
Market Drivers
3/31/2023 to 4/10/2026| Return | Correlation | |
|---|---|---|
| GMED | 59.6% | |
| Market (SPY) | 63.3% | 36.8% |
| Sector (XLV) | 19.1% | 34.1% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GMED Return | 11% | 3% | -28% | 55% | 6% | 5% | 40% |
| Peers Return | -7% | -11% | -3% | 7% | 9% | -2% | -8% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| GMED Win Rate | 58% | 75% | 42% | 58% | 33% | 75% | |
| Peers Win Rate | 47% | 47% | 50% | 50% | 52% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| GMED Max Drawdown | -8% | -26% | -41% | -7% | -37% | -4% | |
| Peers Max Drawdown | -16% | -26% | -19% | -8% | -13% | -10% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, SYK, JNJ, ZBH, OFIX. See GMED Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)
How Low Can It Go
| Event | GMED | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -47.9% | -25.4% |
| % Gain to Breakeven | 92.0% | 34.1% |
| Time to Breakeven | 374 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -41.0% | -33.9% |
| % Gain to Breakeven | 69.6% | 51.3% |
| Time to Breakeven | 253 days | 148 days |
| 2018 Correction | ||
| % Loss | -33.7% | -19.8% |
| % Gain to Breakeven | 50.8% | 24.7% |
| Time to Breakeven | 343 days | 120 days |
Compare to MDT, SYK, JNJ, ZBH, OFIX
In The Past
Globus Medical's stock fell -47.9% during the 2022 Inflation Shock from a high on 9/8/2021. A -47.9% loss requires a 92.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Globus Medical (GMED)
AI Analysis | Feedback
Here are 1-3 brief analogies for Globus Medical (GMED):
- Like Stryker or Zimmer Biomet for spine, joint, and trauma surgical implants.
- The Medtronic of orthopedic and spine surgical solutions.
- Johnson & Johnson, but exclusively focused on musculoskeletal medical devices.
AI Analysis | Feedback
- Spine Products: A range of traditional fusion implants including pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating various spinal conditions.
- Motion Preservation Technologies: Devices such as dynamic stabilization, total disc replacement, and interspinous distraction devices designed to maintain spinal motion.
- Interventional Pain Management Solutions: Products developed to treat vertebral compression fractures.
- Regenerative Biologic Products: Allografts and synthetic alternatives used to promote healing and regeneration.
- Orthopedic Trauma Products: Solutions including fracture plates, compression screws, intramedullary nails, and external fixation systems for treating fractures and orthopedic injuries.
- Hip and Knee Joint Solutions: Implants such as modular hip stems, acetabular cups, and various knee arthroplasty implants for joint replacement.
- Human Cell, Tissue, and Cellular and Tissue-based Products: Distributed human cell, tissue, and cellular and tissue-based products.
AI Analysis | Feedback
Major Customers of Globus Medical (GMED)
Globus Medical, Inc. (GMED) primarily sells its medical devices and solutions to healthcare institutions rather than directly to individual patients. Due to the fragmented nature of the medical device industry, Globus Medical typically does not have a single major customer that accounts for a significant portion of its revenue, nor does it typically disclose specific customer names. Instead, its customer base comprises a broad network of:
- Hospitals: These are the primary institutions where surgical procedures utilizing Globus Medical's spine, trauma, and joint replacement products are performed.
- Ambulatory Surgical Centers (ASCs): Outpatient facilities that perform various surgical procedures, including those requiring Globus Medical's devices.
- Group Purchasing Organizations (GPOs): While not direct end-users, GPOs act as intermediaries, negotiating purchasing contracts on behalf of hospitals and other healthcare providers, thereby influencing where these institutions procure their medical supplies.
AI Analysis | Feedback
nullAI Analysis | Feedback
Keith Pfeil, President and Chief Executive Officer
Keith Pfeil has served as President and Chief Executive Officer of Globus Medical since July 2025. He joined Globus as Chief Financial Officer in August 2019, and in 2024, he was named Executive Vice President, Chief Operating Officer, and Chief Financial Officer. Prior to joining Globus, Mr. Pfeil spent approximately 16 years at CSS Industries, Inc., a publicly traded consumer products company, where he most recently served as Executive Vice President and Chief Financial Officer.
Kyle Kline, Senior Vice President and Chief Financial Officer
Kyle Kline has served as Senior Vice President and Chief Financial Officer since July 2025. He joined Globus Medical in May 2017 as Assistant Controller and has held roles of increasing responsibility in accounting and finance, including Senior Vice President of Finance, where he led the company's day-to-day accounting, finance, treasury, and tax functions.
David C. Paul, Executive Chairman
David C. Paul is the founder of Globus Medical, having established the company in 2003. He served as Chief Executive Officer from inception until August 2017, when he transitioned to the role of Executive Chairman. Prior to founding Globus, Mr. Paul was employed at Synthes, where his last position was Director of Product Development, responsible for product development and marketing functions. He is named inventor on over 300 patents and published applications.
Kelly G. Huller, Esquire, General Counsel
Kelly Huller has served as General Counsel since December 2018. She began her career at Globus in 2006 as the company's first in-house counsel. During her tenure, Ms. Huller has led more than 10 mergers and acquisitions, including the company's acquisition of NuVasive, Inc.
Brian Kearns, Senior Vice President, Business Development and Investor Relations
Brian Kearns has served as Senior Vice President of Business Development and Investor Relations for Globus Medical since January 2015. In this role, he is responsible for sourcing, evaluating, negotiating, and integrating all mergers and acquisitions, as well as investor relations and corporate communications. Before joining Globus, Mr. Kearns founded Kearns Consulting LLC in 2009, a consulting company that provided corporate development and strategic planning services to small to mid-sized healthcare companies. His prior experience also includes serving as CFO of a publicly traded generic pharmaceutical company and a publicly traded healthcare services company, as well as holding equity research positions at Salomon Smith Barney (now Citi) and Bank of America, and financial management roles at Johnson & Johnson. An SEC complaint related to his time as CFO of MedQuist was settled in 2009.
AI Analysis | Feedback
Here are the key risks to Globus Medical's business:
- Integration Risks from the NuVasive Acquisition: Globus Medical's 2023 merger with NuVasive presents significant integration challenges that could disrupt operations and hinder expected synergies. These challenges include difficulties in consolidating manufacturing, rationalizing stock-keeping units (SKUs), harmonizing ERP systems, and aligning salesforces, which can defer anticipated benefits and distract commercial teams. The company experienced supply chain disruptions in Q1 2025 due to the active integration phase, which may have impacted order fulfillment and led to increased competitive pressure. Furthermore, there is a risk of sales representative attrition due to uncertainty about roles within the combined entity. Successful integration is crucial for achieving planned cross-selling opportunities, cost efficiencies, and margin expansion.
- Regulatory Challenges and Compliance Issues: The medical device industry is subject to stringent regulatory requirements, and Globus Medical has recently faced compliance issues. The company received a warning letter from the U.S. Food and Drug Administration (FDA) in July 2024, following an inspection that identified deficiencies in product complaint procedures. These deficiencies included issues with complaint investigations, trending, risk reconciliation, and timely Medical Device Report (MDR) submissions, specifically pertaining to its ExcelsiusGPS® robotic system. This regulatory action led to a drop in the company's stock price and initiated an investigation into potential claims. Changes in regulations, both domestically and internationally, could also impose additional compliance costs or delay product launches.
- Intense Competition and Pricing Pressures: Globus Medical operates in a highly competitive medical device market, particularly in spine, orthopedics, and trauma. The company faces continuous pressure to differentiate its products from those of larger rivals such as Medtronic, DePuy Synthes, Stryker, and Zimmer Biomet. These competitors invest heavily in implants, biologics, and enabling technologies, leading to aggressive pricing strategies and the risk of Globus Medical losing key contracts with hospitals and integrated delivery networks (IDNs). Hospitals are increasingly entering into preferred or exclusive contracts with large suppliers to control costs, which can limit surgeons' choices and exacerbate pricing pressures.
AI Analysis | Feedback
nullAI Analysis | Feedback
Globus Medical (NASDAQ: GMED) operates in several significant addressable markets related to musculoskeletal disorders, including spine products, orthopedic trauma, and hip and knee joint solutions.
Spine Products
The global spine market was valued at approximately $10.8 billion in 2024 and is projected to surpass $12.3 billion by 2028. Other estimates place the global spine market at $12.5 billion in 2024. The spinal implants and surgical devices market was estimated at $14.16 billion in 2024 and is expected to reach $24.50 billion by 2034, growing at a compound annual growth rate (CAGR) of 5.63%. Another report values the spinal implants market at $15.14 billion in 2025, with a projection to reach $24.22 billion by 2033, expanding at a CAGR of 6.08% from 2026 to 2033. The spinal implants and surgical devices market is expected to grow from $13.57 billion in 2025 to $18.05 billion by 2031 at a 4.86% CAGR. The global spinal implants market was valued at $11.31 billion in 2024 and is expected to reach $19.08 billion by 2032, growing at a CAGR of 6.75% from 2025 to 2032. North America accounted for the largest share of the spinal implants market in 2025.
Orthopedic Trauma Products
The global orthopedic trauma devices market is estimated to reach $11.5 billion in 2025 and is predicted to rise to $17.5 billion by 2032, at a CAGR of 6.2%. Another source indicates the global orthopedic trauma device market was valued at $7.4 billion in 2024 and is expected to reach $8.9 billion by 2030, growing at a CAGR of 2.7%. The global orthopedic trauma devices market is projected to increase from $11,140.17 million in 2024 to $17,551.67 million by 2032, reflecting a CAGR of 5.89%. The orthopedic trauma device market is set to reach $12.2 billion in 2026, with a CAGR of 6.4% expected through 2036, totaling $22.6 billion. The global trauma implants market size is projected to be $8624.5 million in 2025 and is projected to reach $14273.51 million by 2033, with a CAGR of 6.50%. The global trauma fixation devices market size was $8.76 billion in 2024 and is projected to surpass $13.03 billion by 2034, with a CAGR of 4.05%. North America is projected to hold the largest share of the orthopedic trauma devices market in 2024, accounting for 41% of the global market.
Hip and Knee Joint Solutions
The global hip and knee replacement market size was $21,412.5 million in 2024, with expectations to expand at a CAGR of 6.00% between 2024 and 2031 to reach $32,196.48 million. Another estimate places the global artificial hip and knee joints market size at $12.57 billion in 2023, projected to grow at a CAGR of 2.85% from 2024 to 2030. The total hip and knee replacements market size was $22.9 billion in 2025 and is expected to grow to $24.05 billion in 2026 at a CAGR of 5.0%, and further to $30.23 billion in 2030 at a CAGR of 5.9%. The global orthopedic large joint device market was valued at over $20.5 billion in 2023 and is expected to reach over $25.7 billion, at a CAGR of 3.3%. The global joint replacement market size was $23.56 billion in 2025 and is predicted to increase to $35.01 billion by 2035, expanding at a CAGR of 4.04% from 2026 to 2035. The global joint replacement devices market is projected to reach $31.1 billion by 2030 from $23.4 billion in 2024, at a CAGR of 4.8%. The hip replacement market alone is expected to grow from $6.92 billion in 2024 to nearly $10.24 billion by 2033, at a CAGR of 4.45% from 2025 to 2033. North America was the largest region in the total hip and knee replacements market in 2025.
AI Analysis | Feedback
Globus Medical (GMED) is poised for future revenue growth over the next 2-3 years, driven by several strategic initiatives and strong performance in key business segments. The company's management and industry analysts have highlighted the following drivers:
- Successful Integration of Acquisitions: The ongoing and successful integration of recent acquisitions, particularly NuVasive and Nevro, is expected to continue boosting Globus Medical's overall trajectory and contribute to its financial performance. The Nevro acquisition, in particular, has been noted for its profitability accretion ahead of schedule.
- Continued Growth and Market Share Gains in the U.S. Spine Business: Globus Medical's U.S. Spine business has consistently demonstrated strong, above-market growth and significant market share gains. This momentum is anticipated to be durable and sustained, serving as a primary organic growth engine for the company.
- Expansion of Enabling Technologies: The Enabling Technologies segment, which includes advanced surgical robotics and navigation systems such as ExcelsiusFlex and the Excelsius XR augmented reality headset, has shown robust performance. This segment is expected to continue its strong growth trajectory, driven by increased adoption and successful deal closures for these innovative systems.
- Robust New Product Pipeline and Innovation: Globus Medical emphasizes a strong commitment to innovation, with a robust pipeline of new products across its musculoskeletal portfolio. Management plans to continue launching new products to address unmet clinical needs, contributing to ongoing profitable growth and market share expansion.
- Sales Force Expansion and Enhanced Market Penetration: The company aims to drive growth by expanding its "high-touch sales force" and improving market penetration. This focus on commercial execution, coupled with ongoing investment in sales and marketing, is expected to increase the reach of Globus Medical's solutions both domestically and internationally.
AI Analysis | Feedback
Share Repurchases
- Globus Medical announced a $500 million share repurchase program authorized by its Board of Directors on May 15, 2025, which has no fixed time limit and can be suspended or discontinued at any time.
- The company utilized this program to repurchase shares, including $225.59 million in Q4 2023, $83.52 million in Q1 2024, and $190.29 million in Q1 2025, $24.99 million in Q2 2025, $39.98 million in Q3 2025, and $44.98 million in Q4 2025.
- The repurchase program is intended to capitalize on perceived undervaluation of the stock and reinforce shareholder value, funded by the company's cash reserves.
Share Issuance
- Globus Medical's shares outstanding significantly increased from 0.103 billion in 2022 to 0.115 billion in 2023 (an 11.68% increase) and further to 0.138 billion in 2024 (a 20.27% increase).
- This increase was largely due to the all-stock transaction for the NuVasive merger, where NuVasive shareholders received 0.75 of a share of Globus Medical Class A common stock for each NuVasive share.
Outbound Investments
- In February 2023, Globus Medical announced a definitive agreement to combine with NuVasive in an all-stock transaction valued at $3.1 billion, which expanded its presence in the spine and musculoskeletal markets and aimed for approximately $170 million in cost synergies.
- The company completed the acquisition of Nevro Corp. for $250 million in April 2025, expanding its addressable market by adding neuromodulation capabilities.
- Globus Medical plans to pursue additional "tuck-in" acquisitions to complement its existing portfolio, focusing on specific technologies rather than very large deals.
Capital Expenditures
- Globus Medical expects capital expenditures to be between 5% and 6% of net sales for 2026.
- The primary focus of these expenditures includes product development, inventory and field sets, and further vertical integration of manufacturing.
- The company made significant investments in machinery, equipment, and sets during Q1 2025 to scale internal manufacturing.
Latest Trefis Analyses
Trade Ideas
Select ideas related to GMED.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
| 05312025 | GMED | Globus Medical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 53.8% | 45.6% | -12.3% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 91.77 |
| Mkt Cap | 65.1 |
| Rev LTM | 16,674 |
| Op Inc LTM | 3,208 |
| FCF LTM | 2,852 |
| FCF 3Y Avg | 2,443 |
| CFO LTM | 3,371 |
| CFO 3Y Avg | 2,963 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.0% |
| Rev Chg 3Y Avg | 8.3% |
| Rev Chg Q | 10.0% |
| QoQ Delta Rev Chg LTM | 2.5% |
| Op Mgn LTM | 18.5% |
| Op Mgn 3Y Avg | 18.6% |
| QoQ Delta Op Mgn LTM | 1.0% |
| CFO/Rev LTM | 20.6% |
| CFO/Rev 3Y Avg | 20.6% |
| FCF/Rev LTM | 17.2% |
| FCF/Rev 3Y Avg | 15.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 65.1 |
| P/S | 3.6 |
| P/EBIT | 17.5 |
| P/E | 23.4 |
| P/CFO | 15.7 |
| Total Yield | 4.7% |
| Dividend Yield | 1.0% |
| FCF Yield 3Y Avg | 4.1% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -0.8% |
| 3M Rtn | -5.9% |
| 6M Rtn | -3.8% |
| 12M Rtn | 3.7% |
| 3Y Rtn | 19.4% |
| 1M Excs Rtn | -1.4% |
| 3M Excs Rtn | -4.4% |
| 6M Excs Rtn | -7.9% |
| 12M Excs Rtn | -31.1% |
| 3Y Excs Rtn | -44.9% |
Comparison Analyses
Price Behavior
| Market Price | $90.42 | |
| Market Cap ($ Bil) | 12.2 | |
| First Trading Date | 08/03/2012 | |
| Distance from 52W High | -6.5% | |
| 50 Days | 200 Days | |
| DMA Price | $88.80 | $74.40 |
| DMA Trend | up | down |
| Distance from DMA | 1.8% | 21.5% |
| 3M | 1YR | |
| Volatility | 26.1% | 52.6% |
| Downside Capture | 0.28 | 0.68 |
| Upside Capture | 47.70 | 123.96 |
| Correlation (SPY) | 30.8% | 29.7% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.01 | 0.74 | 0.78 | 1.13 | 1.00 | 0.96 |
| Up Beta | 0.96 | 0.29 | 1.11 | 0.14 | 0.84 | 0.87 |
| Down Beta | 0.74 | 0.79 | 0.70 | 1.13 | 0.81 | 0.79 |
| Up Capture | 88% | 85% | 82% | 238% | 151% | 128% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 19 | 27 | 56 | 114 | 371 |
| Down Capture | 128% | 76% | 71% | 77% | 119% | 103% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 14 | 23 | 36 | 70 | 137 | 376 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GMED | |
|---|---|---|---|---|
| GMED | 42.8% | 52.8% | 0.85 | - |
| Sector ETF (XLV) | 12.3% | 16.8% | 0.52 | 35.0% |
| Equity (SPY) | 31.2% | 17.3% | 1.47 | 32.4% |
| Gold (GLD) | 60.1% | 27.8% | 1.69 | -0.1% |
| Commodities (DBC) | 29.8% | 16.6% | 1.58 | 1.0% |
| Real Estate (VNQ) | 21.3% | 15.2% | 1.07 | 32.7% |
| Bitcoin (BTCUSD) | -5.7% | 43.7% | -0.01 | 18.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GMED | |
|---|---|---|---|---|
| GMED | 9.3% | 37.3% | 0.33 | - |
| Sector ETF (XLV) | 6.3% | 14.6% | 0.25 | 41.1% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 44.4% |
| Gold (GLD) | 22.1% | 17.8% | 1.02 | 5.7% |
| Commodities (DBC) | 11.8% | 18.8% | 0.52 | 11.5% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 38.7% |
| Bitcoin (BTCUSD) | 4.0% | 56.5% | 0.29 | 17.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GMED | |
|---|---|---|---|---|
| GMED | 15.2% | 35.2% | 0.50 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 42.6% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 45.8% |
| Gold (GLD) | 14.2% | 15.9% | 0.74 | 3.5% |
| Commodities (DBC) | 8.6% | 17.6% | 0.41 | 16.3% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.22 | 39.3% |
| Bitcoin (BTCUSD) | 67.4% | 66.9% | 1.07 | 9.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/24/2026 | 4.7% | -0.2% | -4.9% |
| 11/6/2025 | 35.9% | 36.1% | 43.3% |
| 7/21/2025 | -7.9% | -3.3% | 6.9% |
| 5/8/2025 | -23.0% | -20.2% | -16.7% |
| 2/20/2025 | -4.6% | -6.5% | -12.5% |
| 11/5/2024 | 9.4% | 10.4% | 9.9% |
| 8/6/2024 | 2.1% | -2.5% | 2.5% |
| 5/7/2024 | 20.2% | 22.4% | 28.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 12 | 12 |
| # Negative | 11 | 12 | 12 |
| Median Positive | 5.4% | 9.7% | 10.7% |
| Median Negative | -4.2% | -4.7% | -5.5% |
| Max Positive | 35.9% | 36.1% | 43.3% |
| Max Negative | -23.0% | -20.2% | -29.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 02/20/2025 | 10-K |
| 09/30/2024 | 11/05/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/21/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/04/2023 | 10-Q |
| 12/31/2022 | 02/21/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/24/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 3.18 Bil | 3.20 Bil | 3.22 Bil | 0 | Affirmed | Guidance: 3.20 Bil for 2026 | |
| 2026 Non-GAAP Diluted EPS | 4.4 | 4.45 | 4.5 | 2.3% | Raised | Guidance: 4.35 for 2026 | |
Prior: Q4 2025 Earnings Reported 1/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 3.18 Bil | 3.20 Bil | 3.22 Bil | 11.1% | Higher New | Guidance: 2.88 Bil for 2025 | |
| 2026 EPS | 4.3 | 4.35 | 4.4 | 14.5% | Higher New | Guidance: 3.8 for 2025 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Norwalk, Leslie V | Direct | Sell | 12162025 | 88.85 | 4,000 | 355,400 | 1,103,428 | Form | |
| 2 | Kline, Kyle | Senior Vice President, CFO | Direct | Sell | 12032025 | 90.00 | 18,542 | Form | ||
| 3 | Huller, Kelly | SVP, GC, Corporate Secretary | Direct | Sell | 11282025 | 90.00 | 7,500 | Form | ||
| 4 | Davidar, David D | Direct | Sell | 11132025 | 86.00 | 25,000 | 2,150,005 | 44,399,753 | Form | |
| 5 | Zarrilli, Stephen T | Direct | Sell | 11132025 | 84.29 | 25,000 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.